The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | The future of MRD-adapted and genomics-informed treatment in high-risk myeloma
Benjamin Diamond, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses the future of measurable residual disease (MRD)-adapted and genomics-informed treatment strategies in high-risk multiple myeloma. Dr Diamond highlights increasing MRD negativity rates with emerging therapies and the growing accessibility of genomic testing, emphasizing how combining these approaches could support more personalized treatment decisions in newly diagnosed and relapsed disease. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
